Pomerantz Law Firm Investigates Evolus, Inc. Following FDA Warning Letter
Pomerantz LLP has launched an investigation into Evolus, Inc. (NASDAQ: EOLS) following a warning letter from the U.S. Food and Drug Administration (FDA). The regulatory body flagged Instagram promotional content for Jeuveau, the company's wrinkle treatment, as false or misleading. The FDA specifically objected to claims that minimized safety risks—including boxed warnings regarding toxin spread—and made unsubstantiated promises about product efficacy and speed of results. Following the disclosure of this warning on October 2, 2026, Evolus shares dropped by 7.15% to close at $7.14. The investigation seeks to determine if Evolus or its executives engaged in securities fraud or other unlawful business practices related to these disclosures.
Tickers: $EOLS
Topics: Class Action Lawsuit FDA Warning Letter Misleading Advertising Securities Fraud Investigation